ArticleClinical nuclear medicine2026
Prognostic Value of a Semi-Quantitative Score Based on 123 I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the prognostic significance of a semi-quantitative scoring system derived from 123 I-Metaiodobenzylguanidine ( 123 I-MIBG) SPECT/CT imaging in predicting clinical outcomes for pediatric patients with stage 4 high-risk neuroblastoma after induction therapy.
methodsA retrospective analysis was conducted on a cohort of 116 pediatric patients diagnosed with stage 4 high-risk neuroblastoma. All patients received induction therapy and subsequently underwent 123 I-MIBG SPECT/CT imaging in our department. The Curie score and relevant clinical indicators were assessed, and both univariate and multivariate Cox proportional hazards models were applied to identify independent risk factors associated with disease recurrence. The optimal cutoff value for the Curie score was determined using the Youden index. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
resultsAccording to the Youden index, the optimal cutoff value for Curie score after induction therapy was established as 6. Patients with a Curie score >6 (n=29) exhibited significantly lower PFS and OS compared with those with a Curie score≤6 (n=87). Specifically, 1-year PFS was 55.2%±9.2% versus 79.3%±4.3%, and 3-year PFS was 15.1%±8.3% versus 54.7%±5.9% ( P <0.001). Similarly, 1-year OS was 70.0%±18.2% versus 89.9%±5.6%, and 3-year OS was 0.0% versus 60.0%±11.8% ( P =0.002). Multivariate Cox regression analysis revealed that a Curie score >6, the presence of neuroblastoma pathology, MYCN amplification, and 11q23 aberration were independent predictors of poor prognosis. Among patients with MYCN-amplified neuroblastoma, a higher Curie score (>6) was significantly associated with worse clinical outcomes.
conclusionsThis study demonstrates that the Curie score derived from 123 I-MIBG SPECT/CT imaging after induction therapy is strongly associated with the prognosis of pediatric patients with MIBG-avid stage 4 high-risk neuroblastoma. Notably, patients achieving a Curie score of 6 or lower after induction therapy may benefit from subsequent consolidation and maintenance treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.